Detail akcie CytomX Therapeutics online

Business Summary: CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Financial Summary: BRIEF: For the three months ended 31 March 2026, CytomX Therapeutics Inc revenues decreased 80% to $10.3M. Net loss totaled $18.2M vs. income of $23.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Stock-based Compensation in SGA increase from $1.4M to $3.8M (expense), Research and development increase of 11% to $18.3M (expense).